Drug resistance and immunotherapy in gynecologic cancers
Sarojamma Vemula1, Sabeerabi Bonala2, Neha Krishna Vadde1
1Government Medical College, Anantapur, Andhra Pradesh, India.
Abstract:
Gynecologic malignancies (GMs) are relatively less focused cancers by oncologists and researchers. The five-year survival rate of patients with GMs remained almost the same during the last decade. The development of drug resistance GMs makes it even more challenging to tackle due to tumor heterogeneity, genomic instability, viral/non-viral antigens, and etiological tumor origin. A precision medicine approach, including gene therapies, is under testing to restore tumor responsiveness to therapeutics and immunotherapy. With more data being uncovered, immunotherapy is emerging as a viable alternative for achieving promising results. This review highlights the drug resistance mechanisms and immunotherapeutic approaches to managing GMs better. The approval of immune therapeutic drugs in recent years shifted this notion. It provided hope for researchers, clinicians, and patients with GMs to experience the anti-cancer benefits of these therapies.
Insights
Gynecologic malignancies (GMs) show poor survival rates due to drug resistance. Immunotherapy offers a promising approach to overcome resistance and improve treatment outcomes for GM patients.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Gynecologic malignancies (GMs) represent a group of cancers with stagnant survival rates over the past decade.
- Drug resistance, driven by tumor heterogeneity and genomic instability, significantly complicates GM treatment.
- Current therapeutic strategies for GMs have limited efficacy, necessitating novel treatment modalities.
Purpose of the Study:
- To review the mechanisms of drug resistance in gynecologic malignancies.
- To explore the potential of immunotherapy as a treatment strategy for GMs.
- To highlight recent advancements in managing GMs with a focus on immunotherapy.
Main Methods:
- Literature review of studies on gynecologic malignancies, drug resistance, and immunotherapy.
- Analysis of mechanisms underlying therapeutic resistance in GMs.
- Examination of preclinical and clinical data on immunotherapeutic approaches for GMs.
Main Results:
- Drug resistance in GMs is multifactorial, involving tumor heterogeneity, genomic instability, and antigen-related factors.
- Immunotherapy has emerged as a promising alternative, showing potential to overcome resistance and improve patient outcomes.
- Recent approvals of immune therapeutic drugs offer new hope for managing GMs.
Conclusions:
- Understanding drug resistance mechanisms is crucial for developing effective GM treatments.
- Immunotherapy represents a significant advancement in the management of gynecologic malignancies.
- Precision medicine approaches, including gene therapies and immunotherapy, are vital for improving survival rates in GMs.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...